title: Galanin receptor 1 deletion exacerbates hippocampal neuronal loss after systemic kainate administration in mice.
abstract: BACKGROUND
  Galanin is a neuropeptide with a wide distribution in the central and peripheral nervous systems and whose physiological effects are mediated through three G protein-coupled receptor subtypes, GalR1, GalR2, and GalR3. Several lines of evidence indicate that galanin, as well as activation of the GalR1 receptor, is a potent and effective modulator of neuronal excitability in the hippocampus.
  
  
  RESULTS
  In order to test more formally the potential influence of GalR1 on seizure-induced excitotoxic cell death, we conducted functional complementation tests in which transgenic mice that exhibit decreased expression of the GalR1 candidate mRNA underwent kainate-induced status epilepticus to determine if the quantitative trait of susceptibility to seizure-induced cell death is determined by the activity of GalR1. In the present study, we report that reduction of GalR1 mRNA via null mutation or injection of the GalR1 antagonist, galantide, prior to kainate-induced status epilepticus induces hippocampal damage in a mouse strain known to be highly resistant to kainate-induced neuronal injury. Wild-type and GalR1 knockout mice were subjected to systemic kainate administration. Seven days later, Nissl and NeuN immune- staining demonstrated that hippocampal cell death was significantly increased in GalR1 knockout strains and in animals injected with the GalR1 antagonist. Compared to GalR1-expressing mice, GalR1-deficient mice had significantly larger hippocampal lesions after status epilepticus.
  
  
  CONCLUSIONS
  Our results suggest that a reduction of GalR1 expression in the C57BL/6J mouse strain renders them susceptible to excitotoxic injury following systemic kainate administration. From these results, GalR1 protein emerges as a new molecular target that may have a potential therapeutic value in modulating seizure-induced cell death.
authors.affiliation: Department of Cell and Neurobiology, University of Southern California Keck School of Medicine, Los Angeles, California, United States of America. schauwec@usc.edu
authors.forename: P Elyse
authors.initials: PE
authors.lastname: Schauwecker
mesh_terms: D000818:Animals; D019004:Galanin / Q000737:chemistry; D017353:Gene Deletion; D005838:Genotype; D006624:Hippocampus / Q000378:metabolism*; D007608:Kainic Acid / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009474:Neurons / Q000378:metabolism*; D009479:Neuropeptides / Q000737:chemistry; D012333:RNA, Messenger / Q000378:metabolism; D044091:Receptor, Galanin, Type 1 / Q000235:genetics*; D013226:Status Epilepticus / Q000378:metabolism
chemical_list: D009479:Neuropeptides; D012333:RNA, Messenger; D044091:Receptor, Galanin, Type 1; D019004:Galanin; D007608:Kainic Acid